Genelux Corporation
GNLXHealthcare|Biotechnology|US
$1.96
+0.14 (+7.69%)
Tangible Book / Share
$0.36
Cash / Share
$0.42
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer | P3 | Recruiting | 186 | RCT, Open-label | olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar) |
| NCT06463665 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma | P2 | Recruiting | 142 | RCT, Open-label | Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel |
| NCT07136285 Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC | SCLC, Extensive Stage | P1P2 | Recruiting | 27 | Open-label | Olvi-Vec, platinum (cisplatin or carboplatin), Etoposide |
| NCT02759588 Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | Ovarian Cancer, Peritoneal Carcinomatosis | P1P2 | Completed | 46 | Open-label | Olvi-Vec, Platinum-doublet with or without bevacizumab |
| NCT01443260 A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis | Peritoneal Carcinomatosis | P1P2 | Completed | 9 | Open-label | GL-ONC1 |
| NCT02714374 GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers | Solid Organ Cancers | P1 | Terminated | 5 | Open-label | GL-ONC1 |
| NCT00794131 Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | Advanced Cancers (Solid Tumors) | P1 | Completed | 43 | Open-label | GL-ONC1 |
| NCT01766739 Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma | Lung Cancer | P1 | Completed | 18 | Open-label | GL-ONC1 |
| NCT01584284 Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer | Cancer of Head and Neck | P1 | Completed | 19 | Open-label | GL-ONC1 |
| NCT03420430 Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care | Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), Acute Myeloid Leukemia (6 Patients) | NO_LONGER_AVAILABLE | — | — | GL-ONC1 |